Landmark Australian Research Uncovers Potential HTLV-1 Prevention and Treatment Strategies Using Existing HIV Drugs

Around 10 million people globally live with the human T-cell leukemia virus type 1 (HTLV-1), a pervasive yet poorly understood retrovirus that currently lacks preventative treatments and a cure. This silent global health threat disproportionately affects vulnerable populations, remaining an overlooked challenge in infectious disease research. However, a landmark study co-led by Australian researchers from the Walter and Eliza Hall Institute of Medical Research (WEHI) and the Peter Doherty Institute for Infection and Immunity (Doherty Institute) is poised to fundamentally alter this landscape, revealing that existing HIV drugs can effectively suppress HTLV-1 transmission in living organisms and identifying a novel drug target with curative potential.

Published in the prestigious journal Cell, the findings represent a significant leap forward in the quest to control and ultimately eliminate HTLV-1. The study’s dual breakthrough – demonstrating the efficacy of readily available HIV antivirals against HTLV-1 and pinpointing a new mechanism to eradicate infected cells – could pave the way for the world’s first treatments to prevent the spread of this virus. This is particularly critical for communities where HTLV-1 is endemic, including numerous First Nations communities globally and specifically in Central Australia, where infection rates can be alarmingly high.

Understanding HTLV-1: A Neglected Global Health Challenge

Human T-cell leukemia virus type 1 (HTLV-1) is a retrovirus that, much like HIV, targets T cells – a critical type of white blood cell essential for the body’s immune response. While the majority of infected individuals remain asymptomatic carriers for life, approximately 5-10% will, after a prolonged latency period often spanning decades, develop severe, life-threatening conditions. These include adult T-cell leukemia/lymphoma (ATL), an aggressive and often fatal cancer of the blood, and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), a debilitating neurological disorder causing progressive spinal cord inflammation and paralysis. Other associated conditions can include uveitis, infective dermatitis, and bronchiectasis.

The virus is primarily transmitted in three ways: from mother to child (through breastfeeding), sexually, and through contaminated blood products (transfusions, needle sharing). Its global distribution is concentrated in specific "hotspots," including southwestern Japan, parts of the Caribbean basin, areas of sub-Saharan Africa, regions of South America, and, notably, among Indigenous populations in Central Australia. Despite its significant burden, HTLV-1 has historically suffered from a severe lack of awareness, research funding, and public health initiatives compared to other retroviruses like HIV. This neglect stems from several factors, including its slow disease progression, the asymptomatic nature of most infections, and its higher prevalence in communities that often face systemic health inequities and limited access to healthcare.

A Decade of Groundbreaking Research and a World-First Model

The collaborative research effort that culminated in this landmark study spanned over a decade, representing a sustained commitment to addressing this neglected disease. A pivotal achievement in this journey was the development of a world-first humanized mouse model for HTLV-1. This sophisticated model, spearheaded by first author Dr. James Cooney and Professor Marc Pellegrini – a study lead author, WEHI Honorary Fellow, and Executive Director at Centenary Institute – allowed researchers to study the complex interplay between the virus and a human-like immune system within a living organism.

The process involved transplanting human immune cells, specifically susceptible T cells, into immunodeficient mice. Crucially, the researchers were able to infect these mice with various HTLV-1 strains, including Australia’s genetically distinct HTLV-1c strain, alongside international HTLV-1a strains. This innovative approach provided an unprecedented platform to observe the virus’s behavior, understand its pathogenesis, and evaluate potential therapeutic interventions in a dynamic biological system, moving beyond traditional in vitro (test tube) studies. Both the international and Australian strains were found to cause severe diseases in these human immune system mice, including leukemia and inflammatory lung disease, validating the model’s relevance to human pathology.

Repurposing HIV Drugs: A Direct Path to Prevention

With this robust in vivo model established, the research team, led by co-lead author and WEHI laboratory head Dr. Marcel Doerflinger, set out to test existing antiviral therapies. Their focus quickly turned to two drugs already widely used and approved for HIV treatment and prevention: tenofovir and dolutegravir. These drugs belong to classes of antivirals that target different stages of the retroviral life cycle, specifically inhibiting reverse transcriptase (tenofovir) and integrase (dolutegravir), enzymes crucial for viral replication.

The results were profoundly encouraging. When the HTLV-1-infected humanized mice were treated with tenofovir and dolutegravir, the researchers discovered that both drugs could powerfully suppress the HTLV-1 virus. Dr. Doerflinger emphasized the transformative potential of this discovery: "Our study marks the first time any research group has been able to suppress this virus in a living organism." He further highlighted the critical timing of intervention: "As HTLV-1 symptoms can take decades to appear, by the time a person knows they have the infection the immune damage is already in full swing. Suppressing the virus at transmission would allow us to stop it before it has the chance to cause irreversible damage to immune function, leading to disease and a premature death."

The immediate clinical relevance of these findings cannot be overstated. "What’s most exciting is that these antivirals are already in use for millions of HIV patients, meaning there’s a direct path for the clinical translation of our findings," Dr. Doerflinger stated. This pre-existing knowledge of the drugs’ safety profile, pharmacokinetics, and efficacy in humans significantly accelerates the development timeline. Unlike starting from scratch with a new compound, these drugs have undergone extensive clinical trials and are well-understood, dramatically reducing the time and cost typically associated with drug development. This offers a tangible and rapid pathway to the first approved pre-exposure prophylaxis (PrEP) against HTLV-1 acquisition, a preventative measure that could halt new infections and profoundly impact disease burden.

A Dual Strategy: Eliminating Infected Cells for a Potential Cure

Beyond preventing transmission, the research uncovered another remarkable finding with implications for those already living with established HTLV-1 infection. The team discovered that human cells containing HTLV-1 could be selectively killed when the infected mice were treated with HIV drugs in combination with another therapy that inhibits a protein called MCL-1. MCL-1 is a pro-survival protein, often overexpressed in cancer cells, which helps rogue cells evade apoptosis (programmed cell death).

This combination therapy represents a potential paradigm shift, moving beyond mere viral suppression to the targeted elimination of infected cells. The ability to selectively kill HTLV-1 positive cells offers a glimmer of hope for a curative strategy, particularly for individuals at risk of developing ATL or HAM/TSP. The research team is now actively leveraging precision RNA therapies to develop new ways to specifically target MCL-1 and establish combination treatments that can be clinically tested. They believe this innovative approach could offer a promising curative strategy for HTLV-1, potentially preventing disease progression in those already infected and mitigating the long-term health consequences.

The Australian Context: HTLV-1c and First Nations Communities

The study holds particular significance for Australia, where HTLV-1 is highly endemic within certain First Nations communities in Central Australia. This region is home to a unique and genetically distinct subtype of the virus, known as HTLV-1c. The research provided crucial insights into this specific strain, demonstrating its ability to cause aggressive disease features in the humanized mouse models, sometimes even more so than the internationally prevalent HTLV-1a strains. Importantly, the identified drug therapies were found to be equally effective against both HTLV-1c and HTLV-1a, offering a universal solution.

The development of the human HTLV-1 samples necessary for these mouse models was made possible through the dedicated front-line clinical work of Associate Professor Lloyd Einsiedel, a Clinician Scientist at the Doherty Institute and an Infectious Diseases Physician. For over a decade, Assoc. Prof. Einsiedel has provided essential clinical services to Central Australia and has dedicated his career to raising the profile of HTLV-1, meticulously collecting samples that were vital for this research.

Professor Damian Purcell, Head of Molecular Virology at the Doherty Institute and a co-lead author of the study, played a crucial role in isolating the virus from First Nations donors and meticulously identifying the significant genetic differences between the Central Australian HTLV-1c strains and the international HTLV-1a strains. Prof. Pellegrini underscored the importance of this: "It’s long been hypothesized that differences in viral subtype may influence disease outcomes, but a lack of research into HTLV-1 has made it difficult for us to find the evidence needed to support this claim – until now." He added, "Our study provides critical insights that enable us to better understand the consequences of the distinct molecular make-up of the virus affecting our First Nations communities. This will further help us to investigate ways to create the tools needed to control the spread of this virus subtype."

Advocacy and Global Recognition: A Decades-Long Battle

The scientific breakthroughs are built upon a foundation of persistent advocacy for a disease that has been largely ignored. Prof. Purcell and Assoc. Prof. Einsiedel, working closely with the National Aboriginal Community Controlled Health Organization (NACCHO) HTLV-1 committee and the Australian Department of Health, spearheaded a tireless campaign over many years to advocate for greater recognition from the World Health Organization (WHO). This concerted effort culminated in a pivotal moment in 2021 when the WHO formally classified HTLV-1 as a "Threatening Pathogen to Humans."

This crucial classification was a game-changer, elevating HTLV-1 onto the global health agenda. It subsequently led to the development of formal WHO policies aimed at reducing international transmission and, locally, the establishment of clinical management guidelines for HTLV-1c in Central Australia under the leadership of NACCHO. These policy changes are vital steps, but as Prof. Purcell highlighted, significant challenges remain. "Despite Australia’s high burden of HTLV-1, the virus and its associated diseases are still not notifiable in most states and true infection rates in the nation remain unknown," he noted. This lack of comprehensive surveillance hinders effective public health responses and resource allocation.

Broader Implications and the Path Forward

The findings of this Australian-led research carry profound implications that extend beyond the immediate scientific discovery. They offer a blueprint for addressing other neglected tropical diseases and underscore the power of collaborative, multidisciplinary research. The direct applicability of existing HIV drugs dramatically shortens the translational pathway, offering a realistic hope for rapid clinical implementation.

The research team is already in active discussions with the pharmaceutical companies behind the HIV antivirals used in this study. The goal is to explore the possibility of including HTLV-1 patients in their ongoing clinical trials. If successful, this integration would be a monumental step, potentially paving the way for these drugs to become the first officially approved pre-exposure prophylaxis against HTLV-1 acquisition. This would provide a critical tool for public health initiatives, especially in high-prevalence areas, to prevent new infections and reduce the overall burden of HTLV-1.

"People at risk from HTLV-1 deserve biomedical tools like those that provide game-changing therapeutic and prevention options for other blood-borne persistent viral infections, such as HIV," Prof. Purcell asserted. "There is a real opportunity to prevent the transmission of HTLV-1 and end the diseases caused by these infections. Our research findings are a major leap forward in this."

The sustained support from various funding bodies, including The Australian Center for HIV and Hepatitis Virology Research, The Phyllis Connor Memorial Trust, Drakensberg Trust, and the National Health and Medical Research Council (NHMRC), has been instrumental in bringing this decade-long endeavor to fruition. This research not only offers immediate hope for millions but also sets a precedent for how global health challenges, particularly those affecting marginalized communities, can be effectively tackled through dedicated science, innovative models, and relentless advocacy. The vision is clear: to move HTLV-1 from the shadows of neglect into the light of effective prevention and potential cure.